Accumulate Divis Laboratories; target of Rs 7050: Prabhudas Lilladher

Prabhudas Lilladher's research report on Divis Laboratories

Divi’s Laboratories (DIVI) Q2FY26 EBITDA was a beat; 7% above our estimates led by higher CS revenues. We expect margins to improve, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP’s and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates broadly remain unchanged.

Outlook

We expect 20% EBITDA CAGR and 19% PAT CAGR over FY25-28E. At CMP, stock is trading at 53x Sept2027E EPS. We Maintain our ‘Accumulate’ rating with revised TP of Rs7,050/share, valuing at 55x Sept 2027E EPS.